Limited data exist on outcomes in mRCC patients with major venous involvement (MVI). Assessment of impact of a given variable on prognosis in cancer patients is challenging given competing causes of ...

OPTIC-RCC trial used RNA sequencing to identify angiogenic tumors, showing improved outcomes with cabozantinib and nivolumab, ...

Source: Getty Images Improving survival rates for patients with sarcomatoid differentiation can be attributed to advances in immunotherapy, according to researchers. The overall survival rate at 5 ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

Mortality risk in clinical T1a renal cell carcinoma (RCC) with synchronous metastasis (SM): A comparative analysis of National Cancer Database (NCDB). This is an ASCO Meeting Abstract from the 2025 ...

Purpose Cytoreductive nephrectomy (CN) has played a role in treatment of metastatic renal cell carcinoma (mRCC) since trials demonstrated a survival benefit in patients receiving CN with interferon.

In an observational study of second-line therapies for metastatic RCC, overall survival and time-to-treatment failure data favored cabozantinib. A European analysis of second-line therapies for ...

High LAG3 RNA expression in metastatic RCC is associated with improved ORR but not significant OS benefit, indicating adaptive immune resistance. Tumors with high LAG3 levels show robust infiltration ...

Nivolumab/cabozantinib showed superior progression-free and overall survival compared to sunitinib in advanced RCC, with a median follow-up of 67.6 months. The combination therapy demonstrated higher ...

Sarcomatoid renal cell carcinoma (sRCC) is an aggressive form of kidney cancer that can be found in at least 20 percent of advanced kidney tumors and has high rates of metastasis. sRCC arises through ...